Agomelatine, A Potential Multi-Target Treatment Alternative for Insomnia, Depression, and Osteoporosis in Postmenopausal Women: A Hypothetical Model

• DOI: 10.3389/fpsyt.2021.654616
• Publication Date: 2021-06-29T04:53:43Z
• Authors: Ahmet Yardimci; Mehmet Ridvan Ozdede; Haluk Kelestimur
• Keywords: Depression; Agomelatine; Premenstrual dysphoric disorder

Insomnia, which is associated with menopausal depression, a common symptom of menopause. Both symptoms have etiology, and can affect each other significantly. Pharmacological interventions, including hypnotics antidepressants, non-pharmacological therapies are generally administered in clinical practice for insomnia treatment. As another disorder, osteoporosis described as disease low bone mineral density (BMD), affecting nearly 200 million women worldwide. Postmenopausal among middle-aged women. Since postmenopausal mainly results from estrogen levels, hormone therapy (HT) considered the first-line option prevention during period. However, almost no study has evaluated novel treatments combined insomnia, osteoporosis. Hence, it necessary to develop new multi-target strategies treatment these disorders improve quality life this vulnerable Melatonin major regulator sleep, been suggested be safe effective loss by MT-2 receptor activity. result, we hypothesize that agomelatine, an MT-1 agonist 5-HT 2C antagonist, holds promise